August 01, 2016
Article
Treatment with anthracyclines was proven to be beneficial for patients with high-risk, HER2-negative, early-stage breast cancer.
July 21, 2016
Article
Phase III results of the KRISTINE trial demonstrated that patients with HER2-positive early breast cancer had a significantly higher pathological complete response (pCR) rate when they received the neoadjuvant regimen of docetaxel, carboplatin, and trastuzumab plus pertuzumab (TCH+P) versus trastuzumab emtansine (T-DM1) plus pertuzumab (T-DM1+P).
June 10, 2016
Article
In patients with HER2-positive early breast cancer, data from a phase III trial has shown a significantly higher pathological complete response (pCR) rate with neoadjuvant docetaxel plus carboplatin plus trastuzumab plus pertuzumab versus trastuzumab emtansine plus pertuzumab.
June 08, 2016
Article
Interim analysis of a clinical trial of multiplex gene testing for inherited cancer risk suggests that fears of unnecessary surgery or adverse psychological effects associated with testing may be unwarranted.
June 06, 2016
Article
A joint analysis of the "ABC" trials comparing anthracycline versus non-anthracycline treatment in patients with high-risk, HER2-negative breast cancer has failed to demonstrate non-inferiority of the non-anthracycline regimen.
December 10, 2015
Article
A combination of venetoclax and obinutuzumab, followed by additional cycles of venetoclax, has shown tolerability in elderly patients with previously untreated chronic lymphocytic leukemia with comorbidities, data from the CLL14 trial (BO25323) shows.